Bilaketaren emaitzak - Santos Carvajal‐Gonzalez
- Erakusten 1 - 5 emaitzak -- 5
-
1
-
2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study nork Arthur Bergman, Santos Carvajal‐Gonzalez, Sanela Tarabar, Aditi R. Saxena, William P. Esler, Neeta B. Amin
Argitaratua 2020Artigo -
3
-
4
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems nork Trenton T. Ross, Collin Crowley, Kenneth L. Kelly, Anthony Rinaldi, David A. Beebe, Matthew P. Lech, Robert V. Martinez, Santos Carvajal‐Gonzalez, Magalie Boucher, Dinesh Hirenallur‐Shanthappa, Jeffrey Morin, Alan Opsahl, Sarah Regina Vargas, Kendra K. Bence, Jeffrey A. Pfefferkorn, William P. Esler
Argitaratua 2020Artigo -
5
Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes nork David A. Griffith, Daniel W. Kung, William P. Esler, Paul A. Amor, Scott W. Bagley, Carine Beysen, Santos Carvajal‐Gonzalez, Shawn D. Doran, Chris Limberakis, Alan M. Mathiowetz, Kirk McPherson, David A. Price, Éric Ravussin, Gabriele E. Sonnenberg, James A. Southers, Laurel J. Sweet, Scott Turner, F.F. Vajdos
Argitaratua 2014Artigo
Bilaketa egiteko lanabesak:
Antzeko gaiak
Medicine
Chemistry
Internal medicine
Biochemistry
Biology
Enzyme
Insulin
Pharmacology
Acetyl-CoA carboxylase
Adverse effect
Beta oxidation
Disease
Endocrinology
Fatty liver
Lipogenesis
Metabolism
Nonalcoholic fatty liver disease
Pharmacodynamics
Pharmacokinetics
Postprandial
Pyruvate carboxylase
Steatohepatitis
Steatosis
Tolerability
Agonist
Alternative medicine
Biotechnology
Diacylglycerol kinase
Fibrosis
Gastric emptying